AR054583A1 - PANTOPRAZOL ISOTOPICALLY REPLACED - Google Patents

PANTOPRAZOL ISOTOPICALLY REPLACED

Info

Publication number
AR054583A1
AR054583A1 ARP060103223A ARP060103223A AR054583A1 AR 054583 A1 AR054583 A1 AR 054583A1 AR P060103223 A ARP060103223 A AR P060103223A AR P060103223 A ARP060103223 A AR P060103223A AR 054583 A1 AR054583 A1 AR 054583A1
Authority
AR
Argentina
Prior art keywords
replaced
pantoprazol
isotopically
compounds
solvates
Prior art date
Application number
ARP060103223A
Other languages
Spanish (es)
Inventor
Bernhard Kohl
Bernd Muller
Dieter Haag
Wolfgang-Alexander Simon
Karl Zech
Michael David
Richter Oliver Von
Felix Huth
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of AR054583A1 publication Critical patent/AR054583A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se refiere a compuestos de la formula (1) y a medicamentos que comprenden estos compuestos, adicionalmente a intermediarios. Reivindicacion 1: Compuestos de la formula general (1) en la cual R1 es difluorometoxi, R2 es metoxi; R3 es metoxi; y sales, solvatos, preferiblemente hidratos y solvatos, preferiblemente hidratos de las sales de los mismos, en donde al menos uno de los átomos de H de R1, R2, R3 o cualquier combinacion de R1, R2 y R3 está reemplazado por un átomo de deuterio.It refers to compounds of the formula (1) and to drugs comprising these compounds, in addition to intermediates. Claim 1: Compounds of the general formula (1) in which R1 is difluoromethoxy, R2 is methoxy; R3 is methoxy; and salts, solvates, preferably hydrates and solvates, preferably hydrates of the salts thereof, wherein at least one of the H atoms of R1, R2, R3 or any combination of R1, R2 and R3 is replaced by an atom of deuterium.

ARP060103223A 2005-07-26 2006-07-26 PANTOPRAZOL ISOTOPICALLY REPLACED AR054583A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05106874 2005-07-26

Publications (1)

Publication Number Publication Date
AR054583A1 true AR054583A1 (en) 2007-06-27

Family

ID=35708921

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103223A AR054583A1 (en) 2005-07-26 2006-07-26 PANTOPRAZOL ISOTOPICALLY REPLACED

Country Status (8)

Country Link
EP (1) EP1912947A1 (en)
JP (1) JP5289951B2 (en)
CN (1) CN101268050B (en)
AR (1) AR054583A1 (en)
AU (1) AU2006274037B2 (en)
CA (1) CA2615678C (en)
TW (1) TWI410409B (en)
WO (1) WO2007012651A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016814B1 (en) * 2005-07-26 2012-07-30 Никомед Гмбх Isotopically substituted proton pump inhibitors
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
WO2008127300A2 (en) * 2006-10-23 2008-10-23 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
US7943620B2 (en) * 2007-03-07 2011-05-17 Concert Pharmaceuticals, Inc. Anti-anginal compounds
PL2345653T3 (en) * 2007-05-01 2013-05-31 Concert Pharmaceuticals Inc Morphinan compounds
EP3825306B8 (en) 2007-05-01 2023-08-02 Sun Pharmaceutical Industries, Inc. Morphinan compounds
EP2155697B1 (en) * 2007-06-13 2012-11-28 Auspex Pharmaceuticals, Inc. Substituted piperazines
EP2242493B1 (en) * 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Derivatives of gefitinib
JP5770997B2 (en) * 2009-12-09 2015-08-26 大塚製薬株式会社 Method for measuring metabolic function of CYP3A4
CN103349655B (en) * 2013-07-22 2015-04-29 南通广泰生化制品有限公司 Tamoxifen citrate enteric capsules
MX2017002750A (en) * 2014-09-02 2017-08-02 Singh Bhupinder Deuterated or a non-deuterated molecule and pharmaceutical formulations.
GB2560750A (en) * 2017-03-24 2018-09-26 Taher Darreh Shori Biological methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) * 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
ZA854287B (en) * 1984-06-16 1986-02-26 Byk Gulden Lomberg Chem Fab Dialkoxypyridines,process for their preparation,their use and medicaments containing them
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (en) * 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 Deuterated compound and composition for treating hypertension
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
NO309305B1 (en) * 1999-02-19 2001-01-15 Norsk Hydro As Use of benzaldehyde derivatives in the manufacture of pharmaceutical preparations for the prevention and / or treatment of cancer, as well as certain new benzaldehyde derivatives
DE10123129A1 (en) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterated 3-piperidinopropiophenones and medicinal products containing these compounds
DE10162121A1 (en) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterated substituted pyrazolyl-benzenesulfonamides and drugs containing these compounds
EA016814B1 (en) * 2005-07-26 2012-07-30 Никомед Гмбх Isotopically substituted proton pump inhibitors

Also Published As

Publication number Publication date
CN101268050A (en) 2008-09-17
JP2009502872A (en) 2009-01-29
JP5289951B2 (en) 2013-09-11
AU2006274037A1 (en) 2007-02-01
CA2615678C (en) 2015-01-20
TW200745039A (en) 2007-12-16
WO2007012651A1 (en) 2007-02-01
AU2006274037B2 (en) 2012-04-26
TWI410409B (en) 2013-10-01
CN101268050B (en) 2012-11-28
EP1912947A1 (en) 2008-04-23
CA2615678A1 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
AR054583A1 (en) PANTOPRAZOL ISOTOPICALLY REPLACED
ECSP099395A (en) NEW DERIVATIVES OF AMINO-NICOTINIC AND AMINO-ISONICOTINIC ACIDS
CU23926B1 (en) DERIVATIVE OF OXOPIRAZINE AND HERBICIDE
AR052568A1 (en) DERIVATIVES OF PIRAZOLO-PYRIMIDINE AS ANGLOSTS OF MGLUR2
CY1109911T1 (en) PYRROLOVENZODIAZEPINES
ECSP10010368A (en) UREA DERIVATIVES OF TETRAHIDROQUINOXALINA, YOUR PREPARATION
CO6150142A2 (en) BEZOXAZOLES AND OXAZOLOPIRIDINS THAT ARE USEFUL AS INHIBITORS OF JANUS KINASES
CO5700820A2 (en) DERIVATIVES OF DIOXAN-2-ALQUILCARBAMATOS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
CO6251235A2 (en) COMPOUNDS DERIVED FROM AZETIDINES ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
BRPI0606480A (en) pharmaceutical compounds
AR055635A1 (en) USE OF SULFONANILIDS AS HERBICIDES
GT200500286A (en) ANILINO-PYRIMIDINE ANALOGS
AR061548A1 (en) 3-AMINOPIRROLIDINO-4-REPLACED LACTAMAS AS INHIBITORS OF DIPEPTIDILPEPTIDASA IV (DPP-IV), PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME IN THE TREATMENT OF DIABETES II.
UY29742A1 (en) PROCEDURE FOR THE PREPARATION OF BETAMIMETICS
EA200800701A1 (en) 4-substituted pyrrolidin-2-one and their application
EA200801365A1 (en) SUBSTITUTED 5-PHENYL-3,6-DIGIDRO-2-OXO-6H-1,3,4-TIADIAZINS
CO6321168A2 (en) NEW DERIVATIVES OF 2-AMIDOTIADIAZOL
UY29749A1 (en) SELECTED CGRP ANTAGONISTS, PROCEDURES FOR THEIR PREPARATION, AS WELL AS ITS USE AS MEDICATIONS
ES2557477T3 (en) New cyclic peptide compounds
UY29070A1 (en) FUSIONED HETEROCYCLIC ENANTIOMERS AND THEIR USES
AR044342A1 (en) BENCIMIDAZOL DERIVATIVES
UY30009A1 (en) BENZOILPIRAZOL AND HERBICIDE COMPOUNDS CONTAINING THEM
CO6341610A2 (en) AROMATIC HETEROCICLYL COMPOUND CONTAINING NITROGEN.
AR073043A1 (en) COMPOUNDS OF POLYSUSTITUTED AZETIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHOD OF PREPARATION AND USE OF THE SAME IN THE TREATMENT OF RESPIRATORY, METABOLIC DISEASES AND OF THE CENTRAL NERVOUS SYSTEM, AMONG OTHERS.
EA200801366A1 (en) DERIVATIVES 3,6-DIGIDRO-2-OXO-6N-1,3,4-TIADIAZINA

Legal Events

Date Code Title Description
FB Suspension of granting procedure